Table 1:
Baseline Characteristics of CRIC participants overall and by opioid and NSAID use
| Opioid use at baseline | NSAID use at baseline | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No (n=3548) | Yes (n=391) | P | No (n=3327) | Yes (n=612) | P | |||||
| Age (years) | 0.3 | 0.003 | ||||||||
| 21-<45 | 494 (13.9%) | 44 (11.3%) | 462 (13.9%) | 76 (12.4%) | ||||||
| 45-<65 | 2025 | (57.1) | 236 | (60.4) | 1872 | (56.3) | 389 | (63.6) | ||
| 65+ | 1029 | (29.0) | 111 | (28.4) | 993 | (29.8) | 147 | (24.0) | ||
| Male sex | 2004 | (56.5) | 157 | (40.2) | <0.001 | 1908 | (57.3) | 253 | (41.3) | <0.001 |
| Black race | 1472 | (41.5) | 186 | (47.6) | 0.02 | 1432 | (43.0) | 226 | (36.9) | 0.005 |
| Diabetes | 1720 | (48.5) | 188 | (48.1) | 0.9 | 1668 | (50.1) | 240 | (39.2) | <0.001 |
| Hypertension | 3062 | (86.3) | 329 | (84.1) | 0.2 | 2892 | (86.9) | 499 | (81.5) | <0.001 |
| Any cardiovascular disease | 1159 | (32.7) | 157 | (40.2) | 0.003 | 1156 | (34.7) | 160 | (26.1) | <0.001 |
| Rheumatoid Arthritisa | 411 | (12.2) | 81 | (22.3) | <0.001 | 404 | (12.8) | 88 | (15.1) | 0.1 |
| Asthmab | 419 | (12.0) | 79 | (20.5) | <0.001 | 401 | (12.3) | 97 | (16.1) | 0.01 |
| Cancer (excluding non-melanoma skin cancer | 168 | (4.7) | 28 | (7.2) | 0.04 | 167 | (5.0) | 29 | (4.7) | 0.8 |
| Drinking alcohol | 743 | (20.9) | 50 | (12.8) | <0.001 | 649 | (19.5) | 144 | (23.5) | 0.02 |
| Prior visit with nephrologist | 2328 | (65.6) | 273 | (69.8) | 0.1 | 2295 | (69.0) | 306 | (50.0) | <0.001 |
| Educationc | 0.06 | <0.001 | ||||||||
| Less than high school | 752 | (21.2) | 76 | (19.4) | 739 | (22.2) | 89 | (14.6) | ||
| High school graduate | 660 | (18.6) | 81 | (20.7) | 631 | (19.0) | 110 | (18.0) | ||
| Some college | 1015 | (28.6) | 131 | (33.5) | 955 | (28.7) | 191 | (31.3) | ||
| College graduate or higher | 1120 | (31.6) | 103 | (26.3) | 1002 | (30.1) | 221 | (36.2) | ||
| Income | 0.006 | 0.001 | ||||||||
| $20,000 or under | 1102 | (31.1) | 138 | (35.3) | 1082 | (32.5) | 158 | (25.8) | ||
| $20,001 - $50,000 | 847 | (23.9) | 111 | (28.4) | 809 | (24.3) | 149 | (24.3) | ||
| $50,001 - $100,000 | 673 | (19.0) | 61 | (15.6) | 603 | (18.1) | 131 | (21.4) | ||
| More than $100,000 | 369 | (10.4) | 23 | (5.9) | 311 | (9.3) | 81 | (13.2) | ||
| Don’t wish to answer | 557 | (15.7) | 58 | (14.8) | 522 | (15.7) | 93 | (15.2) | ||
| Non-opioid/non-NSAID analgesic use | 560 | (15.8) | 114 | (29.2) | <0.001 | 532 | (16.0) | 142 | (23.2) | <0.001 |
| Tramadol use | 72 | (2.0) | 18 | (4.6) | 0.001 | 73 | (2.2) | 17 | (2.8) | 0.4 |
| Anxiolytic used | 107 | (3.0) | 38 | (9.7) | <0.001 | 109 | (3.3) | 36 | (5.9) | 0.002 |
| Anti-epileptic usee | 289 | (8.2) | 95 | (24.3) | <0.001 | 315 | (9.5) | 69 | (11.3) | 0.2 |
N=3939. Values given to count (percent).
a)
197 missing
b)
312 missing for opioid use and 69 missing for NSAID use
c)
76 missing for opioid use and 1 missing for NSAID use
d)
353 missing for opioid use and 28 missing for NSAID use
e)
296 missing for opioid use and 28 missing for NSAID use